The ACOSOG (Alliance) Z11102 (NCT01556243) phase II single arm prospective trial evaluated how well breast-conserving surgery and radiation therapy worked in treating patients with multiple ipsilateral breast cancer. In this touchONCOLOGY interview, we speak with Prof. Judy Boughey (Mayo Clinic, Rochester, MN, USA) who gives an overview on multiple ipsilateral breast cancer and also discusses the ACOSOG (Alliance) Z11102 trial.
The abstract entitled ‘Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – Results from ACOSOG Z11102 (Alliance)’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.
Questions:
- Could you tell us a little about multiple ipsilateral breast cancer (MIBC) and its improved detection? (0:14)
- What is known about the optimal surgical management of MIBC? (0:36)
- What were the aims, design and eligibility criteria of the ACOSOG Z11102 study? (1:23)
- What were the primary and secondary outcome measures, and how well were they achieved? (2:30)
- What factors impacted local recurrence? (3:48)
Disclosures: Judy Boughey discloses grant/research support from Eli Lilly
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen
Filmed as a highlight of SABCS 2022
Access more content on Breast Cancer
